Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novartis AG Common Stock (NY:NVS)

163.92 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Feb 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,793
Open 163.92
Bid (Size) 162.68 (400)
Ask (Size) 162.78 (800)
Prev. Close 163.92
Today's Range 163.92 - 163.92
52wk Range 97.72 - 167.86
Shares Outstanding N/A
Dividend Yield 2.44%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Pfizer’s BRAFTOVI BREAKWATER Trial Delivers Landmark Survival Gains in Colorectal Cancer
NEW YORK — Pfizer Inc. (NYSE: PFE) has announced breakthrough results from its Phase 3 BREAKWATER clinical trial, demonstrating that its BRAFTOVI (encorafenib) regimen significantly improves both... 
Via MarketMinute
Novartis AG-Sponsored ADR (NYSE:NVS): A Quality Dividend Stock with Strong Fundamentals ↗
Via Chartmill

Performance

YTD
+18.3%
+18.3%
1 Month
+14.2%
+14.2%
3 Month
+31.8%
+31.8%
6 Month
+29.3%
+29.3%
1 Year
+53.3%
+53.3%

More News

Read More
News headline image
A Look Into Novartis Inc's Price Over Earnings ↗
Via Benzinga
News headline image
Promethos Capital Liquidates $4 Million Sprouts Farmers Market Position: Should Investors Sell, Too? ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Buy 2 Vanguard Index Funds to Beat the S&P 500 in the Next Decade, According to Wall Street Analysts ↗
Via The Motley Fool
Topics ETFs Stocks
News headline image
Novartis Says Conditionally Approved Kidney Drug Shows Long-Term Promise ↗
Via Benzinga
News headline image
Alnylam Pharmaceuticals (ALNY): The RNAi Pioneer’s 2026 Breakout and the Battle for Cardiovascular Dominance
Via Finterra
Topics Economy Intellectual Property
News headline image
Incyte (INCY) Deep Dive: Navigating the 2026 Crossroads Following Earnings Miss
Via Finterra
Topics Economy Intellectual Property
News headline image
Biogen (BIIB) Q4 Earnings Preview: The "New Biogen" Emerges as Alzheimer's and Rare Disease Pipelines Take Center Stage
Via MarketMinute
Topics Intellectual Property
News headline image
The Era of the Titans: Q4 2025 Mega-Deal Surge and the 2026 Economic Map
Via MarketMinute
Topics Artificial Intelligence Economy
News headline image
Biogen (BIIB) Deep Dive: Navigating the Pivot from MS Giant to Neuro-Innovation Powerhouse
Via Finterra
Topics Earnings Economy Intellectual Property
News headline image
Arrowhead (ARWR) Q1 2026 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Novartis (NVS) Q3 2024 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Novartis Faces Biggest Patent Expiry Ever but Sees Growth Ahead ↗
Via Benzinga
Topics Intellectual Property
News headline image
Stock Market Today, Feb. 3: Novo Nordisk Slides as Pricing Pressure Clouds Obesity-Drug Outlook ↗
Via The Motley Fool
Topics Initial Public Offering Intellectual Property Stocks
Veteran Biopharma Engineer Ge Yang Attracts Investor Interest with Vision to Redefine Global Pharma Manufacturing
Via AB Newswire
News headline image
This Vanguard ETF Has Doubled the S&P 500's Returns Since the Start of 2025. Is It a Buy Now? ↗
Via The Motley Fool
Topics ETFs Stocks
News headline image
Peering Into Novartis AG's Recent Short Interest ↗
Via Benzinga
News headline image
The Biological Singularity: How AlphaFold 3 Is Rewriting the Blueprint of Drug Discovery
Via TokenRing AI
Topics Artificial Intelligence
News headline image
Even Near an All-Time High, This Dividend ETF Looks Extremely Cheap ↗
Via The Motley Fool
Topics ETFs
News headline image
The Biological Singularity: How Nobel-Winning AlphaFold 3 is Rewriting the Blueprint of Life
Via TokenRing AI
Topics Artificial Intelligence Economy
News headline image
Lilly Bolsters Immunology Arsenal with $1.2 Billion Acquisition of Ventyx Biosciences
Via MarketMinute
News headline image
The Master Architect of Molecules: How Google DeepMind’s AlphaProteo is Rewriting the Blueprint for Cancer Therapy
Via TokenRing AI
Topics Artificial Intelligence
News headline image
Why I Am Buying the Schwab International Equity ETF (SCHF) and Never Looking Back ↗
Via The Motley Fool
Topics ETFs Economy
News headline image
The Silicon Laureates: How the 2024 Nobel Prizes Rewrote the Rules of Scientific Discovery
Via TokenRing AI
Topics Artificial Intelligence

Frequently Asked Questions

Is Novartis AG Common Stock publicly traded?
Yes, Novartis AG Common Stock is publicly traded.
What exchange does Novartis AG Common Stock trade on?
Novartis AG Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Novartis AG Common Stock?
The ticker symbol for Novartis AG Common Stock is NVS on the New York Stock Exchange
What is the current price of Novartis AG Common Stock?
The current price of Novartis AG Common Stock is 163.92
When was Novartis AG Common Stock last traded?
The last trade of Novartis AG Common Stock was at 02/19/26 07:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.